

SUPPLEMENTARY DATA

Supplementary Figure S1. Selection process of the study individuals



SUPPLEMENTARY DATA

Supplementary Figure S2. Hazard ratio (solid line) and 95% confidence interval (dashed lines) of mortality associated with first metformin daily dose in individuals with post-pancreatitis diabetes mellitus



SUPPLEMENTARY DATA

Supplementary Table S1. Associations between the use of antidiabetic medications and cause-specific mortality in individuals with diabetes of the exocrine pancreas

	Cardiovascular mortality			Cancer mortality			Other		
	No. of deaths (%)	Crude HR (95% CI)	Adjusted HR (95% CI)	No. of deaths (%)	Crude HR (95% CI)	Adjusted HR (95% CI)	No. of deaths (%)	Crude HR (95% CI)	Adjusted HR (95% CI)
Insulin use									
Post-pancreatitis diabetes mellitus									
No antidiabetic medications	27 (10.5)	1.00	1.00	23 (8.9)	1.00	1.00	208 (80.6)	1.00	1.00
Never insulin	22 (5.8)	0.40 (0.23-0.71)	0.64 (0.35-1.16)	23 (6.1)	0.54 (0.30-0.96)	0.72 (0.39-1.33)	332 (88.1)	0.75 (0.63-0.89)	0.72 (0.60-0.86)
Ever insulin	10 (5.0)	0.28 (0.14–0.59)	0.82 (0.37–1.83)	17 (8.5)	0.67 (0.36-1.27)	1.52 (0.74–3.10)	174 (86.6)	0.58 (0.47-0.71)	0.53 (0.42–0.66)
Pancreatic cancer-related diabetes									
No antidiabetic medications	7 (2.4)	1.00	1.00	241 (81.7)	1.00	1.00	47 (15.9)	1.00	1.00
Never insulin	3 (1.0)	0.21 (0.05-0.81)	0.25 (0.06-1.01)	246 (84.5)	0.52 (0.44-0.62)	0.59 (0.49-0.71)	42 (14.4)	0.46 (0.30-0.70)	0.44 (0.28-0.68)
Ever insulin	7 (1.6)	0.26 (0.09–0.74)	0.31 (0.10–0.93)	335 (76.1)	0.41 (0.35–0.49)	0.46 (0.39–0.55)	98 (22.3)	0.54 (0.38–0.77)	0.51 (0.35–0.74)
Metformin use									
Post-pancreatitis diabetes mellitus									
No antidiabetic medications	27 (10.5)	1.00	1.00	23 (8.9)	1.00	1.00	208 (80.6)	1.00	1.00
Never metformin	8 (10.0)	0.65 (0.29-1.43)	0.97 (0.42-2.21)	6 (7.5)	0.67 (0.27-1.64)	0.91 (0.35-2.36)	66 (82.5)	0.63 (0.47-0.83)	0.61 (0.46-0.81)
Ever metformin	24 (4.8)	0.31 (0.18–0.54)	0.61 (0.34–1.11)	34 (6.8)	0.58 (0.34-0.98)	0.90 (0.50-1.60)	440 (88.4)	0.69 (0.58-0.81)	0.67 (0.56–0.79)
Pancreatic cancer-related diabetes	, ,	,	,	, ,	,	,	, ,	,	,
No antidiabetic medications	7 (2.4)	1.00	1.00	241 (81.7)	1.00	1.00	47 (15.9)	1.00	1.00
Never metformin	3 (1.8)	0.29 (0.07-1.15)	0.28 (0.07-1.16)	131 (77.1)	0.44 (0.35-0.54)	0.44 (0.35-0.55)	36 (21.2)	0.43 (0.27-0.67)	0.41 (0.26-0.64)
Ever metformin	7 (1.3)	0.22 (0.08–0.64)	0.29 (0.09–0.86)	450 (80.2)	0.46 (0.39-0.54)	0.54 (0.46-0.63)	104 (18.5)	0.55 (0.39-0.78)	0.53 (0.37–0.78)

Abbreviations: HR: hazard ratio, CI: confidence interval

Footnotes: Adjusted hazard ratios were from multivariable Cox regression models including age, sex, ethnicity, alcohol consumption, tobacco smoking, social deprivation index, and the Charlson comorbidity index. The 'ever insulin' subgroup included individuals who were prescribed insulin alone or in combination with other antidiabetic medications.